来自官方财务报表的收入、利润与现金流历史。
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $776M | $638M | $386M | $271M | $50M | $9M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| 毛利 | $724M | $591M | $352M | $245M | $45M | ($1M) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| 毛利率% | 93.3% | 92.6% | 91.4% | 90.4% | 89.6% | -13.1% | — | — | — | — | — | — | — | — |
| 营业利润（EBIT） | ($189M) | ($169M) | ($281M) | ($232M) | ($180M) | ($125M) | ($99M) | ($67M) | ($33M) | ($27M) | ($28M) | ($9M) | ($6M) | ($2M) |
| 营业利润率% | -24.4% | -26.5% | -72.7% | -85.7% | -359.3% | -1414.0% | — | — | — | — | — | — | — | — |
| 净利 | ($192M) | ($183M) | ($287M) | ($239M) | ($187M) | ($135M) | ($103M) | ($68M) | ($31M) | ($29M) | ($27M) | ($12M) | ($6M) | ($2M) |
| 净利润率 % | -24.7% | -28.7% | -74.5% | -88.4% | -374.0% | -1530.0% | — | — | — | — | — | — | — | — |
| EBITDA | — | ($168M) | ($273M) | ($225M) | ($175M) | ($124M) | ($100M) | ($67M) | ($33M) | ($28M) | ($28M) | ($9M) | ($3M) | ($2M) |
| 每股收益（EPS） | $-3.75 | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.59 | $-2.77 | $-2.01 | $-1.15 | $-1.27 | $-1.42 | $-1.02 | $-0.47 | $-0.28 |
| 已发行股数 (M) | — | 50M | 48M | 45M | 41M | 38M | 37M | 34M | 27M | 23M | 19M | 12M | 13M | 8M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 AXSM 交互式查看器。 /companies/us/AXSM
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms